Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.55 |
| ▸ | DRD3 | P35462 | 7/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6164191 | 0.85 | HTR1A (0.57) | DRD3HTR1AHTR7DRD2 | |
| SCHEMBL3476989 | 0.82 | ACHE (0.81) | ACHEDRD3HTR1AHTR7HRH1 | |
| SCHEMBL6783014 | 0.78 | HTR2A (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6776252 | 0.78 | CHRM2 (0.50) | DRD3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL13597056 | 0.78 | CYP2D6 (0.53) | DRD3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL13597055 | 0.77 | CYP2D6 (0.51) | DRD3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14450985 | 0.76 | ACHE (0.57) | ACHEDRD3HTR1AHTR7HRH1 | |
| SCHEMBL29263737 | 0.75 | HPGD (0.59) | ACHEDRD3HTR1AHTR7HRH1 | |
| SCHEMBL19834759 | 0.75 | ACHE (0.57) | ACHEDRD3HTR1AHTR7HRH1 | |
| SCHEMBL6171285 | 0.75 | GAA (0.63) | DRD3HTR1AGAADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029861-A1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | KLINGE PHARMA GMBH | 2004-02-12 | — | — | US | disclosed |
| EP-0912176-B1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-25 | — | — | EP | disclosed |
| US-6451816-B1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | KLINGE PHARMA GMBH (DE) | 2002-09-17 | — | — | US | disclosed |
| EP-0912176-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | Klinge Pharma GmbH (DE) | 1999-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029861-A1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | ALK, IDO1, PDXK | ACHE 4321/4885DRD3 4072/4885HTR1A 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.